Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/7/2025 | $200.00 | Outperform | Raymond James |
1/6/2025 | $173.00 | Buy → Neutral | BofA Securities |
10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
4/29/2024 | Mkt Perform → Outperform | William Blair | |
1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
1/20/2022 | $150.00 → $126.00 | Equal-Weight | Morgan Stanley |
12/22/2021 | $162.00 → $156.00 | Overweight | Wells Fargo |
12/20/2021 | $148.00 → $145.00 | Buy | Deutsche Bank |
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of America's Most Responsible Companies 2025 by Newsweek for the sixth consecutive year. Aptar is ranked number 71 out of 600 U.S. companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114212847/en/Aptar Named One of America's Most Responsible Companies by Newsweek for the Sixth Consecutive Year (Graphic used with permission from Statista) "We are extremely proud to be recognized by Newsweek for the sixth consecutive year. Many of the world's leading brands tu
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases. Quarterly Conference Calls Press Release (1) Conference Call (2) 4th Quarter and Annual 2024 Results February 6, 2025 February 7, 2025, at 8:00 a.m. CT 1st Quarter 2025 Results May 1, 2025 May 2, 2025, at 8:00 a.m. CT 2nd Quarter 2025 Results July 31, 2025 August 1, 2025, at 8:00 a.m. CT 3rd Quarter 2025
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced their participation at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025. Stephan Tanda, President and CEO, will present at 12:45 p.m. Eastern Standard Time. Vanessa Kanu, Executive Vice President and CFO and Gael Touya, President Aptar Pharma, will also be available. A copy of the presentation will be made available on the Investors page at www.aptar.com. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets in
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases. Quarterly Conference Calls Press Release (1) Conference Call (2) 4th Quarter and Annual 2024 Results February 6, 2025 February 7, 2025, at 8:00 a.m. CT 1st Quarter 2025 Results May 1, 2025 May 2, 2025, at 8:00 a.m. CT 2nd Quarter 2025 Results July 31, 2025 August 1, 2025, at 8:00 a.m. CT 3rd Quarter 2025
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024363414/en/
The Board of Directors of AptarGroup, Inc. (NYSE:ATR) authorized the repurchase of up to $500 million of the Company's common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. Stephan Tanda, President and CEO, commented, "Aptar maintains a balanced approach to capital allocation, focused on returning capital to shareholders, as well as reinvesting in the business through capacity ex
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g
Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00
BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00
Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously